ClinicalTrials.gov
public full text
Public Domain
Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment
The present study is designed for patients with mild COVID-19 phase, to demonstrate if there is a modification in the clinical evolution greater than or equal to 25% in their symptoms, implemented in two groups of patients under an early intervention treatment, a group ( A) will receive Azithromycin / Ivermectin / Ribaroxaban / Paracetamol and another group (B) will receive Azithromycin / Ribaroxaban / Paracetamol followed for 14 days followed by video call
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Caracterisation of COVID-19 Patients Hospitalized in Infectious Disease Department#1365797
- Prognosis and Course of COVID-19 Infection in Hospitalised Patients#910829
- Joint impact of the number of comorbidities and the COVID-19 pandemic on the concordance of antibiotic prescriptions with clinical guidelines, in the community.#1175768
- Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19#1371676
- A Study to Learn About the Use of Paxlovid in Patients With COVID-19 in the Kingdom of Bahrain.#1365260
Record · ID 1212061
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive